Last Orders: What you might have missed on the ASX today
Link copied to
Small caps have dipped for a second day in a row, but they still had a great month.
The Small Ordinaries index of 100 small-cap companies closed Monday down 0.6 per cent to 3,015.6 to finish November up 10.2 per cent for the month.
The ASX200 index meanwhile dropped 1.26 per cent to 6,517.8 on Monday, its third straight day of declines, finishing November up 9.96 per cent – outpacing April as its best month ever.
But microcaps stayed on their winning ways, as the ASX Emerging Companies Index mirrored falls at the big end of town to post a 1.26 per cent gain.
WPP AUNZ (ASX:WPP) was one of the biggest gainers on the ASX on Monday, with shares in the creative transformation agency jumping 35.4 per cent to 55.5c after majority shareholder WPP plc made an unsolicited takeover proposal for 55c per share.
– ImpediMed (ASX:IPD) gained 3.1 per cent to 16c after the medical technology company announced the publication of a “metadata analysis” that shows its bioimpedance spectroscopy technology is very effective in preventing the reoccurrence of chronic breast cancer-related lymphoedema, or limb swelling.
The analysis of 50 studies involving more than 67,000 women showed ImpediMed’s L-Dex measure was 81 per cent more effective in preventing chronic breast cancer-related lymphoedema than tape measure measurements. The analysis is a key step in making L-Dex the standard of care for all patients at risk of developing breast cancer-related lymphoedema.
– Telix Pharmaceuticals (ASX:TLX) gained 7.7 per cent to $3.50 after announcing it had entered into an agreement to buy Swiss-German biotech company TheraPharm GmbH from Scintec Diagnostics GmbH. Telix will pay €10.2 million ($10.6 million) in cash and scrip plus €10 million ($16.2 million) in earn-out components and possible royalties for the company, which has a portfolio of patents and technology in molecularly targeted radiation in hematology and immunology.
– Kyckr (ASX:KYK) was flat at 8.5c after the regulatory technology signed a contract with multinational law firm Clifford Chance, one of the 10 largest law firms in the world. Kyckr will provide the firm’s UK division with onboarding services for an initial rolling 15 month period.
– Neurotech International (ASX:NTI) was flat at 2.9c after announcing final laboratory testing results on its DOLCE/NTI strains of hemp, supporting the company’s belief the cannabis has potent neuro-modulatory and anti-inflammatory potential.
At Stockhead, we tell it like it is. While Neurotech International is a Stockhead advertiser, it did not sponsor this article.